| scholarly article | Q13442814 |
| P819 | ADS bibcode | 2013PLoSO...873453N |
| P356 | DOI | 10.1371/JOURNAL.PONE.0073453 |
| P932 | PMC publication ID | 3767751 |
| P698 | PubMed publication ID | 24039947 |
| P5875 | ResearchGate publication ID | 256614325 |
| P2093 | author name string | Akinori Kimura | |
| Hiroyuki Yamamoto | |||
| Tetsuro Matano | |||
| Midori Nakamura | |||
| Takushi Nomura | |||
| Taeko K Naruse | |||
| Shoi Shi | |||
| Taku Nakane | |||
| P2860 | cites work | Impaired antibody response causes persistence of prototypic T cell-contained virus | Q27331309 |
| Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand | Q29547531 | ||
| Immune-correlates analysis of an HIV-1 vaccine efficacy trial | Q29617377 | ||
| Importance of the nef gene for maintenance of high virus loads and for development of AIDS | Q29618369 | ||
| Post-infection immunodeficiency virus control by neutralizing antibodies | Q33288264 | ||
| Protection of Macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies. | Q33647300 | ||
| Antibody from patients with acute human immunodeficiency virus (HIV) infection inhibits primary strains of HIV type 1 in the presence of natural-killer effector cells | Q33844334 | ||
| Multiple vaccine-elicited nonneutralizing antienvelope antibody activities contribute to protective efficacy by reducing both acute and chronic viremia following simian/human immunodeficiency virus SHIV89.6P challenge in rhesus macaques | Q33966586 | ||
| Passive immunotherapy in simian immunodeficiency virus-infected macaques accelerates the development of neutralizing antibodies | Q34150125 | ||
| Passive neutralizing antibody controls SHIV viremia and enhances B cell responses in infant macaques. | Q34185625 | ||
| Increased HIV-1 vaccine efficacy against viruses with genetic signatures in Env V2 | Q34298408 | ||
| Transfer of neutralizing IgG to macaques 6 h but not 24 h after SHIV infection confers sterilizing protection: implications for HIV-1 vaccine development. | Q34391256 | ||
| Immune failure in the absence of profound CD4+ T-lymphocyte depletion in simian immunodeficiency virus-infected rapid progressor macaques | Q34553778 | ||
| Limited or no protection by weakly or nonneutralizing antibodies against vaginal SHIV challenge of macaques compared with a strongly neutralizing antibody | Q34630446 | ||
| Initial B-cell responses to transmitted human immunodeficiency virus type 1: virion-binding immunoglobulin M (IgM) and IgG antibodies followed by plasma anti-gp41 antibodies with ineffective control of initial viremia | Q34848486 | ||
| Immune escape from HIV-specific antibody-dependent cellular cytotoxicity (ADCC) pressure | Q34937296 | ||
| Antibody-dependent cell-mediated viral inhibition emerges after simian immunodeficiency virus SIVmac251 infection of rhesus monkeys coincident with gp140-binding antibodies and is effective against neutralization-resistant viruses | Q34982646 | ||
| Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys | Q35729899 | ||
| Efficient inhibition of HIV-1 replication in human immature monocyte-derived dendritic cells by purified anti-HIV-1 IgG without induction of maturation | Q35849709 | ||
| Antiviral antibodies are necessary for control of simian immunodeficiency virus replication | Q35857503 | ||
| Association of major histocompatibility complex class I haplotypes with disease progression after simian immunodeficiency virus challenge in burmese rhesus macaques. | Q36086627 | ||
| Cytotoxic T lymphocyte-based control of simian immunodeficiency virus replication in a preclinical AIDS vaccine trial | Q36402663 | ||
| Correlation of vaccine-elicited systemic and mucosal nonneutralizing antibody activities with reduced acute viremia following intrarectal simian immunodeficiency virus SIVmac251 challenge of rhesus macaques | Q37033311 | ||
| Polyfunctional CD4+ T-cell induction in neutralizing antibody-triggered control of simian immunodeficiency virus infection. | Q37191948 | ||
| Contribution of nonneutralizing vaccine-elicited antibody activities to improved protective efficacy in rhesus macaques immunized with Tat/Env compared with multigenic vaccines. | Q37347813 | ||
| The ability of an oligomeric human immunodeficiency virus type 1 (HIV-1) envelope antigen to elicit neutralizing antibodies against primary HIV-1 isolates is improved following partial deletion of the second hypervariable region | Q39602963 | ||
| Nonneutralizing antibodies are able to inhibit human immunodeficiency virus type 1 replication in macrophages and immature dendritic cells | Q40274328 | ||
| Evaluation of passively transferred, nonneutralizing antibody-dependent cellular cytotoxicity-mediating IgG in protection of neonatal rhesus macaques against oral SIVmac251 challenge. | Q40291422 | ||
| In vitro immortalization of Old World monkey T lymphocytes with Herpesvirus saimiri: its susceptibility to infection with simian immunodeficiency viruses | Q41205848 | ||
| Lack of simian immunodeficiency virus (SIV) specific IgA response in the intestine of SIV infected rhesus macaques | Q41814443 | ||
| Broadening of CD8+ cell responses in vaccine-based simian immunodeficiency virus controllers | Q45371512 | ||
| Relationship between antibody-dependent cellular cytotoxicity, plasma HIV type 1 RNA, and CD4+ lymphocyte count. | Q45987356 | ||
| Fc receptor but not complement binding is important in antibody protection against HIV. | Q46545827 | ||
| Diversity of MHC class I genes in Burmese-origin rhesus macaques | Q57178433 | ||
| Passive immune globulin therapy in the SIV/macaque model: early intervention can alter disease profile | Q58477195 | ||
| High resolution HLA class I typing by reference strand mediated conformation analysis (RSCA) | Q77134786 | ||
| Reference strand-mediated conformation analysis-based typing of multiple alleles in the rhesus macaque MHC class I Mamu-A and Mamu-B loci | Q79796528 | ||
| Involvement of Fc gamma RI (CD64) in the mechanism of HIV-1 inhibition by polyclonal IgG purified from infected patients in cultured monocyte-derived macrophages | Q80967901 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 9 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | e73453 | |
| P577 | publication date | 2013-09-09 | |
| P1433 | published in | PLOS One | Q564954 |
| P1476 | title | Limited impact of passive non-neutralizing antibody immunization in acute SIV infection on viremia control in rhesus macaques | |
| P478 | volume | 8 |
| Q37073319 | Biphasic CD8+ T-Cell Defense in Simian Immunodeficiency Virus Control by Acute-Phase Passive Neutralizing Antibody Immunization. |
| Q35973601 | Blockage of CD59 Function Restores Activities of Neutralizing and Nonneutralizing Antibodies in Triggering Antibody-Dependent Complement-Mediated Lysis of HIV-1 Virions and Provirus-Activated Latently Infected Cells |
| Q37512871 | Broadly Neutralizing Antibodies Display Potential for Prevention of HIV-1 Infection of Mucosal Tissue Superior to That of Nonneutralizing Antibodies |
| Q41933652 | In vivo virulence of MHC-adapted AIDS virus serially-passaged through MHC-mismatched hosts. |
| Q64066666 | Mind the Gap: How Interspecies Variability in IgG and Its Receptors May Complicate Comparisons of Human and Non-human Primate Effector Function |
| Q64115950 | Mucosal vaccine efficacy against intrarectal SHIV is independent of anti-Env antibody response |
| Q90411103 | Myeloid Cell-Mediated Trained Innate Immunity in Mucosal AIDS Vaccine Development |
| Q28068018 | Patterns of HIV/SIV Prevention and Control by Passive Antibody Immunization |
| Q55411165 | Uninfected Bystander Cells Impact the Measurement of HIV-Specific Antibody-Dependent Cellular Cytotoxicity Responses. |
| Q34594890 | Vaccine-induced CD107a+ CD4+ T cells are resistant to depletion following AIDS virus infection |
Search more.